Regeneron Pharmaceuticals (REGN) said Thursday it won $135.6 million dollars in compensatory damages and $271.2 million in punitive damages in its antitrust case against Amgen (AMGN).
A jury in the U.S. District Court for the District of Delaware found Amgen using cross-therapeutic bundled rebates to block Regeneron's cholesterol drug Praluent from competing in the market, Regeneron said in a statement.
Amgen allegedly leveraged its anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select its Repatha as the exclusive cholesterol treatment over Praluent, the company said.
"Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent," the company said in the statement.
Amgen didn't immediately respond to a request for comment from MT Newswires.
Regeneron shares rose 2.4% in regular trading Thursday, and Amgen gained 3.6%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.